Parabilis Medicines

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Is Nasdaq becoming the biggest winner of the 2026 IPO market comeback?

Nasdaq’s $129.3 billion first-half listings record strengthens NDAQ’s IPO market story as AI, aerospace, biotech and energy issuers return.

bySoujanya Ravi

July 1, 2026

Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?

Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.

byPallavi Madhiraju

June 10, 2026

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Is Nasdaq becoming the biggest winner of the 2026 IPO market comeback?

Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?